{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:18Z","timestamp":1794047418086,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma- 2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-XL and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-XL and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.<\/jats:p>","DOI":"10.3324\/haematol.2022.280631","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T03:21:01Z","timestamp":1660792861000},"page":"522-531","source":"Crossref","is-referenced-by-count":14,"title":["Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes"],"prefix":"10.3324","volume":"108","author":[{"given":"Melissa A.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Arrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Gbyli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Villaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrida A.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"44596","doi-asserted-by":"crossref","unstructured":"Reidel V, Kauschinger J, Hauch RT. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget. 2018; 9(25):17270-17281.","DOI":"10.18632\/oncotarget.24775"},{"key":"44597","doi-asserted-by":"crossref","unstructured":"Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000; 96(12):3932-3938.","DOI":"10.1182\/blood.V96.12.3932"},{"key":"44598","doi-asserted-by":"crossref","unstructured":"Invernizzi R, Pecci A, Bellotti L, Ascari E. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma. 2001; 42(3):481-489.","DOI":"10.3109\/10428190109064605"},{"key":"44599","doi-asserted-by":"crossref","unstructured":"Jilg S, Reidel V, Muller-Thomas C. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016; 30(1):112-123.","DOI":"10.1038\/leu.2015.179"},{"key":"44600","doi-asserted-by":"crossref","unstructured":"Bhola PD, Letai A. Mitochondria - judges and executioners of cell death sentences. Mol Cell. 2016; 61(5):695-704.","DOI":"10.1016\/j.molcel.2016.02.019"},{"key":"44601","doi-asserted-by":"crossref","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-192.","DOI":"10.1016\/S1535-6108(02)00127-7"},{"key":"44602","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"44603","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"44604","doi-asserted-by":"crossref","unstructured":"Wei AH, Strickland SA, Hou J-Z. Venetoclax combined with low-dose venetoclax for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019; 37(15):1277-1284.","DOI":"10.1200\/JCO.18.01600"},{"key":"44605","doi-asserted-by":"crossref","unstructured":"Ball BJ, Famulare CA, Stein EM. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020; 4(13):2866-2870.","DOI":"10.1182\/bloodadvances.2020001482"},{"key":"44606","doi-asserted-by":"crossref","unstructured":"Zeidan AP, DA Garcia. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood. 2020; 134(Suppl 1):S565.","DOI":"10.1182\/blood-2019-124994"},{"key":"44607","doi-asserted-by":"crossref","unstructured":"Pan R, Ruvolo VR, Wei J. Inhibition of Mcl-1 with the pan-Bcl2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015; 126(3):363-372.","DOI":"10.1182\/blood-2014-10-604975"},{"key":"44608","doi-asserted-by":"crossref","unstructured":"Ramsey HE, Fischer MA, Lee T. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018; 8(12):1566-1581.","DOI":"10.1158\/2159-8290.CD-18-0140"},{"key":"44609","doi-asserted-by":"crossref","unstructured":"Konopleva M, Pollyea DA, Potluri J. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016; 6(10):1106-1117.","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"44610","doi-asserted-by":"crossref","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015; 13:504-513.","DOI":"10.1016\/j.csbj.2015.09.001"},{"key":"44611","doi-asserted-by":"crossref","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017; 33(15):2413-2415.","DOI":"10.1093\/bioinformatics\/btx162"},{"key":"44612","doi-asserted-by":"crossref","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020; 48(W1):W488-W493.","DOI":"10.1093\/nar\/gkaa216"},{"key":"44613","doi-asserted-by":"crossref","unstructured":"Consortium APG. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"44614","doi-asserted-by":"crossref","unstructured":"Malcovati L, Papaemmanuil E, Ambaglio I. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014; 124(9):1513-1521.","DOI":"10.1182\/blood-2014-03-560227"},{"key":"44615","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"44616","doi-asserted-by":"crossref","unstructured":"Chyla B, Daver N, Doyle K. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am J Hematol. 2018; 93(8):E202-E205.","DOI":"10.1002\/ajh.25146"},{"key":"44617","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Tiong IS, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"44618","doi-asserted-by":"crossref","unstructured":"Chen X, Glytsou C, Zhou H. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019; 9(7):890-909.","DOI":"10.1158\/2159-8290.CD-19-0117"},{"key":"44619","doi-asserted-by":"crossref","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925.","DOI":"10.1158\/2159-8290.CD-19-0125"},{"key":"44620","doi-asserted-by":"crossref","unstructured":"Song Y, Rongvaux A, Taylor A. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nat Commun. 2019; 10(1):366.","DOI":"10.1038\/s41467-018-08166-x"},{"key":"44621","doi-asserted-by":"crossref","unstructured":"Das R, Strowig T, Verma R. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med. 2016; 22(11):1351-1357.","DOI":"10.1038\/nm.4202"},{"key":"44622","doi-asserted-by":"crossref","unstructured":"Saito Y, Ellegast JM, Rafiei A. Peripheral blood CD34(+) cells efficiently engraft human cytokine knock-in mice. Blood. 2016; 128(14):1829-1833.","DOI":"10.1182\/blood-2015-10-676452"},{"key":"44623","doi-asserted-by":"crossref","unstructured":"Herold M, Schmalzl F, Zwierzina H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res. 1992; 16(6-7):585-588.","DOI":"10.1016\/0145-2126(92)90006-S"},{"key":"44624","doi-asserted-by":"crossref","unstructured":"Boada M, Echarte L, Guillermo C, Diaz L, Touri\u00f1o C, Grille S. 5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients. Hematol Transfus Cell Ther. 2020; 43(1):35-42.","DOI":"10.1016\/j.htct.2019.12.002"},{"key":"44625","doi-asserted-by":"crossref","unstructured":"Yu H, Borsotti C, Schickel JN. A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood. 2017; 129(8):959-969.","DOI":"10.1182\/blood-2016-04-709584"},{"key":"44626","doi-asserted-by":"crossref","unstructured":"Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res. 2009; 33(8):1011-1016.","DOI":"10.1016\/j.leukres.2009.03.005"},{"key":"44627","doi-asserted-by":"crossref","unstructured":"Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. Leukemia. 2014; 28(5):1142-1145.","DOI":"10.1038\/leu.2013.372"},{"key":"44628","doi-asserted-by":"crossref","unstructured":"Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol. 1994; 87(2):235-242.","DOI":"10.1111\/j.1365-2141.1994.tb04904.x"},{"key":"44629","doi-asserted-by":"crossref","unstructured":"Muguruma Y, Matsushita H, Yahata T. Establishment of a xenograft model of human myelodysplastic syndromes. Haematologica. 2011; 96(4):543-551.","DOI":"10.3324\/haematol.2010.027557"},{"key":"44630","doi-asserted-by":"crossref","unstructured":"Martin MG, Welch JS, Uy GL. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD\/SCID gamma-C chain knockout mice. Leukemia. 2010; 24(9):1662-1664.","DOI":"10.1038\/leu.2010.156"},{"key":"44631","doi-asserted-by":"crossref","unstructured":"Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD\/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004; 103(11):4285-4293.","DOI":"10.1182\/blood-2003-09-3192"},{"key":"44632","doi-asserted-by":"crossref","unstructured":"Benito AI, Bryant E, Loken MR. NOD\/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res. 2003; 27(5):425-436.","DOI":"10.1016\/S0145-2126(02)00221-7"},{"key":"44633","doi-asserted-by":"crossref","unstructured":"Wunderlich M, Chou FS, Link KA. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010; 24(10):1785-1788.","DOI":"10.1038\/leu.2010.158"},{"key":"44634","doi-asserted-by":"crossref","unstructured":"Krevvata M, Shan X, Zhou C. Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica. 2018; 103(6):959-971.","DOI":"10.3324\/haematol.2017.183202"},{"key":"44635","doi-asserted-by":"crossref","unstructured":"Medyouf H, Mossner M, Jann JC. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014; 14(6):824-837.","DOI":"10.1016\/j.stem.2014.02.014"},{"key":"44636","doi-asserted-by":"crossref","unstructured":"Meunier M, Dussiau C, Mauz N. Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes. Oncotarget. 2018; 9(19):14993-15000.","DOI":"10.18632\/oncotarget.24538"},{"key":"44637","doi-asserted-by":"crossref","unstructured":"Rouault-Pierre K, Mian SA, Goulard M. Preclinical modeling of myelodysplastic syndromes. Leukemia. 2017; 31(12):2702-2708.","DOI":"10.1038\/leu.2017.172"},{"key":"44638","doi-asserted-by":"crossref","unstructured":"Moujalled DM, Pomilio G, Ghiurau C. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2018; 33(4):905-917.","DOI":"10.1038\/s41375-018-0261-3"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280631\/74748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280631\/75269","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10747\/74748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:12Z","timestamp":1794045732000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.280631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280631","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}